TMBR insider filings
Timber Pharmaceuticals, Inc. — 40 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-08-22. Screen TMBR transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TMBR between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Timber Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-08-22 | 4 | Koconis John — CEO & Chairman | Grant/award (A): 70,385 @ $0 | EDGAR |
| 2023-08-22 | 4 | Mendelsohn Alan — EVP & CMO | Grant/award (A): 35,193 @ $0 | EDGAR |
| 2023-08-22 | 4 | Lucchese Joseph — EVP & CFO | Grant/award (A): 35,193 @ $0 | EDGAR |
| 2023-04-18 | 4 | Koconis John — CEO & Chairman | Grant/award (A): 45,010 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Gaal Lubor — Director | Grant/award (A): 4,100 @ $0 · Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Mendelsohn Alan — EVP & CMO | Grant/award (A): 22,505 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Pirozzi Gianluca — Director | Grant/award (A): 4,100 @ $0 · Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Sitar Edward J — Director | Grant/award (A): 5,327 @ $0 · Grant/award (A): 5,327 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Lucchese Joseph — EVP & CFO | Grant/award (A): 22,505 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Cohen David E — Director | Grant/award (A): 4,100 @ $0 · Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2022-12-16 | 4 | Sitar Edward J — Director | Grant/award (A): 2,500 @ $1.63 | EDGAR |
| 2022-04-19 | 4 | Mendelsohn Alan — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-04-19 | 4 | Lucchese Joseph — CFO,EVP,Secretary&Treasurer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-04-19 | 4 | Koconis John — CEO & Chairman of the Board, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2022-04-19 | 4 | Sitar Edward J — Director | Grant/award (A): 150,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2022-04-19 | 4 | Pirozzi Gianluca — Director | Grant/award (A): 100,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-04-19 | 4 | Gaal Lubor — Director | Grant/award (A): 100,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-04-19 | 4 | Cohen David E — Director | Grant/award (A): 100,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-04-15 | 4 | Rome Zachary — Director | Option exercise (M): 79,326 @ $0.01 · Tax withholding (F): 19,630 @ $0.28 · Disposition to issuer (D): 52,884 (derivative) @ $0 · Option exercise (M): 79,326 (derivative) @ $0 | EDGAR |
| 2021-12-16 | 4 | Koconis John — CEO & President, Director | Purchase (P): 20,000 @ $0.38 | EDGAR |
| 2021-11-24 | 4 | Mendelsohn Alan — Chief Medical Officer | Purchase (P): 10,000 @ $0.47 | EDGAR |
| 2021-11-24 | 4 | Sitar Edward J — Director | Purchase (P): 15,000 @ $0.46 | EDGAR |
| 2021-09-29 | 4 | Lucchese Joseph — CFO, Executive VP & Treasurer | Grant/award (A): 361,163 (derivative) @ $0 | EDGAR |
| 2021-09-16 | 4 | Rome Zachary — COO, Executive VP & Secretary, Director | Grant/award (A): 561,000 (derivative) @ $0 | EDGAR |
| 2021-09-16 | 4 | Koconis John — CEO & President, Director | Grant/award (A): 890,000 (derivative) @ $0 | EDGAR |
| 2021-09-02 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 225,000 @ $0.94 | EDGAR |
| 2021-09-01 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 100,000 @ $0.93 · Sale (S): 150,000 @ $0.91 · Sale (S): 150,500 @ $0.92 | EDGAR |
| 2021-08-26 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 100,000 @ $0.93 · Sale (S): 100,000 @ $0.91 · Sale (S): 100,000 @ $0.92 | EDGAR |
| 2021-08-20 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 75,000 @ $1.00 · Sale (S): 50,000 @ $0.95 · Sale (S): 50,000 @ $0.91 | EDGAR |
| 2021-07-06 | 4 | Sitar Edward J — Director | Grant/award (A): 47,623 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Pirozzi Gianluca — Director | Grant/award (A): 47,623 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Mendelsohn Alan — Chief Medical Officer | Grant/award (A): 347,991 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Gaal Lubor — Director | Grant/award (A): 71,893 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Cohen David E — Director | Grant/award (A): 71,893 (derivative) @ $0 | EDGAR |
| 2021-06-15 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 146,465 @ $1.27 · Sale (S): 28,450 @ $1.26 | EDGAR |
| 2021-06-10 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 305,540 @ $1.29 · Sale (S): 96,481 @ $1.27 · Sale (S): 185,229 @ $1.26 | EDGAR |
| 2021-06-02 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 47,736 @ $1.27 · Sale (S): 8,670 @ $1.26 · Sale (S): 9,879 @ $1.26 | EDGAR |
| 2021-05-13 | 4 | Mendelsohn Alan — Chief Medical Officer | Purchase (P): 1,988 @ $2.17 | EDGAR |
| 2020-09-16 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 455 @ $1.03 · Sale (S): 87,060 @ $1.03 · Sale (S): 100,694 @ $1.03 | EDGAR |
| 2020-09-14 | 4 | TardiMed Sciences LLC — 10% owner | Sale (S): 32,943 @ $1.04 · Sale (S): 7,483 @ $1.03 | EDGAR |
Recent 8-K events — Timber Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-05-09 | 8-K/A | 1.03 — Bankruptcy or Receivership 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-09 | 8-K | 1.03 — Bankruptcy or Receivership 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-26 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.03 — Bankruptcy or Receivership 2.01 — Completion of Acquisition or Disposition of Assets 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-12-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-28 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TMBR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs